Copay Accumulator Programs Allowed In 2023 Private Insurance Market In Proposed Rule
Executive Summary
Commercial payer programs to undercut manufacturer cost sharing assistance for drugs may continue next year under proposed rule released by the Centers for Medicare and Medicaid Services.
You may also be interested in...
Copay Accumulators: Pending CMS Reg May Offer More Clarity After Judge Limits Scope
Programs only allowed for brands with generic competition under court ruling, but related programs such as copay maximizers and so-called ‘alternative funding’ programs are not directly impacted by the decision.
CMS ‘Safe Harbor’ For Use Of Copay Accumulators In Private Insurance Challenged In Court
Patient groups ‘left with no choice’ but to challenge federal regulation allowing commercial payers to bar manufacturer assistance with drug costs from being counted toward deductibles and out-of-pocket spending caps.
A Case For Transparency: J&J Suit Targets Opaque PBM Affiliate’s Efforts To Exploit Copay Programs
Lawsuit highlights the lack of transparency into pharmacy benefit manager activities and how their programs can influence drug pricing. A Senate hearing on PBMs held shows increasing momentum behind a Federal Trade Commission study on potential anti-competitive activity in the market sector.